Honored to speak today with @IUAA at @LucasOilStadium sharing about my laboratory’s research @TheShieldsLab in small cell lung cancer as one of the 350 cancer researchers at @IUCancerCenter #researchcurescancer @IUBloomington @IUMedSchool @IUIndianapolis @IUgradschool @IUHemOnc @IUIntMed

Join us for a YouTube Live on Friday, June 26, with @charlesrudin (@MSKCancerCenter). Dr. Rudin will discuss how participation in clinical trials has brought hope and meaningful change for people with SCLC. Moderated by @drshieldsmd (@IUScholars) and LUNGevity’s Ann Fish-Steagall, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC. Subscribe to our YouTube Channel now to get notifications of when we are live: lnkd.in/gAy_VGh6 @SclcSMASHERS

During the recent #ASCO26 oncology meeting in Chicago and one day before the oral presentation, I had the opportunity to present the main findings of our study on intracranial efficacy of #Tarlatamab in patients with small-cell lung cancer #SCLC from the DeLLphi-304 trial in a video Interview with @ASCO Post. You can find the 5-minute video link below: 👇 📌 ascopost.com/videos/asco-202… Thank you @ASCO for highlighting our study!! @SclcSMASHERS @OncoAlert @oncodaily @OncBrothers @PeerView @myESMO @IASLC @Amgen @AmgenOncology @LUNGevity @LungCancerEu @YoungLungCancer @fairlifelcc @HeSMO_X @EllokGr @lcsmchat @HenryDunantGR @ConquerCancerFd @LungSummit

Huge congratulations, Doctor. An incredibly well-deserved honor to serve as the #ASCO26 discussant. Your dedication to the Small Cell SMASHERS shines through, and these novel strategies bring genuine hope and progress to patients and families worldwide.

Tarlatamab n=254 vs chemo n=255. 🧠Takeaway: meaningful CNS benefit. CNS PFS, all patients (RECIST, ITT): 🧠median NE (95% CI 13.7–NE) with tarlatamab vs 7.2 mo with chemo. 🧠HR 0.54 (0.39–0.75) 🧠a 46% lower risk of CNS progression or death. #ASCO26 @SclcSMASHERS @ASCO

🧵🪡tarla improved intracranial efficacy OS w/ fewer high-grade AEs vs chemo, supporting use 2L SOC in SCLC, including pt w/ stable, asymptomatic brain mets #ASCO26 #LCSM @ASCO 📌We should not rely on tarla in symptomatic 🧠Met 📌Can we officially put the role of PCI to rest?

OS in patients with brain mets: 13.9 vs 6.8 mo, HR 0.51 (0.34–0.74) 🧠tarlatamab cut risk of death by 49% vs chemo. 🧠Intracranial CR rate and duration of intracranial disease control also favored tarlatamab. #ASCO26 @ASCO #LCSM @SclcSMASHERS #medED

In patients WITH baseline brain mets (mRANO-BM/BICR, tarlatamab n=67 vs chemo n=56): median CNS PFS 6.5 vs 4.2 mo, HR 0.40 (0.24–0.66) 6-mo CNS PFS 53.9% vs 27.0% Small subsets but a 60% risk reduction @ASCO #ASCO26 #LCSM @SclcSMASHERS

From our new antibody–drug conjugates supplement 📗 This comprehensive review summarizes the current active targets for ADCs in extensive-state small cell lung cancer: acsjournals.onlinelibrary.wi… @OncoAlert @NSethakorn @Annechiangmd @SclcSMASHERS

What a happy coincidence! While presenting intracranial efficacy data from DeLLphi-304 in #ASCO26, #Tarlatamab was officially approved in EU!! ✅ In ITT: CNS mPFS NR vs 7.8 m, HR=0.54 ✅ In BM per mRANO: CNS mPFS 6.5 vs 4.2m, HR=0.4 ✅ mOS=13.9 vs 6.8, HR=0.51, independent of baseline BM! A new SoC, hope that all #SCLC patients will soon have access!! #some #LCSM @OncoAlert @OncBrothers @OncLive @PortalOnconews @SclcSMASHERS @myESMO @ASCO @IASCL @PeerView

It was such an honor to co-chair the "Lung Cancer: Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers" session at #ASCO26!! So much incredible data that offers real hope for our patients. I'm especially thankful for our SCLC community! A privilege to share the stage with esteemed colleagues and friends @drshieldsmd @g_mountzios @LaurenByersMD, Dr Gronberg. Tarlatamab's efficacy in treating and preventing brain metastases for our patients is huge. The SEZ6 ADC ABBV-706's responses in heavily pretreated patients offers needed options. Another exhilarating @ASCO , leaving with hope and excitement about the progress we've made and the knowledge that the best is still to come. @SclcSMASHERS @FordePatrick

#ASCO2026: Dr. Giannis Mountzios highlighted the emerging role of tarlatamab in extensive-stage small cell lung cancer, including encouraging data suggesting meaningful CNS disease control in a population with significant unmet needs. @g_mountzios @OncoAlert @ASCO @SclcSMASHERS

Insightful discussion from the Small Cell Lung Cancer Oral Abstract Session at #ASCO2026 came from Dr. Misty Shields, who expertly synthesized the key findings from three important studies and put their clinical implications into perspective. @drshieldsmd @SclcSMASHERS

Dr. @LuisPaz_Ares: biomarkers from phase III IMforte trial of maintenance lurbinectedin in SCLC #ASCO26. PFS & OS benefit of maintenance lurbinectedin seen across molecular subtypes and independent of SLFN11 expression. Suggestion that lurbi may overcome TAM-mediated resistance.

BLESSED BEYOND MEASURE for the opportunity of a LIFETIME to speak at the 2026 @ASCO lung orals session as the discussant on FOUR impactful abstracts focused on novel therapeutic strategies for small cell lung cancer! These trials represent HOPE through progress, dedicated research, discovery, curiosity, and serve as new/future options for our Small Cell SMASHERS & their loved ones. Deeply grateful for this opportunity to highlight the key aspects of each study and how we can use this knowledge to help change/improve the way we treat, care for, and support our patients all over the world impacted by small cell lung cancer. Thank you to every patient, SMASHER, and loved ones who dedicated their lives to be parts of these studies. Because of your courage, altruism, and selflessness, we are one more step closer to limiting loss from small cell lung cancer. #ASCO2026 #researchcurescancer #lcsm #trials #research @SclcSMASHERS @ConquerCancerFd @IUCancerCenter @LUNGevity @TheShieldsLab @LauraAlderMD @FordePatrick @LaurenByersMD @g_mountzios

One of the best parts of #ASCO26? Connecting with friends who truly inspire!! ⭐️ Grateful for tremendous mentorship, amazing collaborators, and 🫁 besties! @BZhangMD @drshieldsmd @jillfeldman4 @EGFRResisters @maraantonoff @Sam_Rosner_ @DDoroshow @LoganRoofMD @BrunaPellini @Jani_Chinmay @KelseyPanMD @chulkimMD @Joshua_Reuss @LudaBazhenovaMD @lungoncdoc @SclcSMASHERS @ASCO @IASLC

🔥Off the press our #ASCO26 poster now in manuscript form #Tarlatamab in Previously Treated Small Cell Lung Cancer: A Real-World Experience in a Predominantly Hispanic Population with CNS Metastases @santiagosucre23 @AmanChauhanMD @Jani_Chinmay @GlopesMd 👉🏽showing meaningful responses activity (ORR 27.7%, DCR 44.4%, median OS 10.6 months), and tolerability in a high risk population (n=23 61% w CNS Mets heavily pretreated ) mdpi.com/3913718 #mdpicancers via @Cancers_MDPI @SclcSMASHERS

With #ASCO26 just around the corner, it is my great pleasure to present in the oral abstract session, alongside prominent colleagues and chairs, the intracranial efficacy data of #tarlatamab from #DeLLphi-304 trial, the first data on CNS efficacy of a T-cell engager in #SCLC. Stay tuned!! 📌 Sunday June 1st, 13:15-16:15, Hall D1 #SoMe #LCSM @SclcSMASHERS @OncoAlert @OncBrothers @PeerView @PortalOnconews @MedscapeOnc @VJOncology @ecancer @LungCancerEu @YoungLungCancer @HeSMO_X @HenryDunantGR

“What does your cancer research lab @TheShieldsLab at @IUCancerCenter study?” We focus exclusively on identifying new biomarkers, targets, and drugs for small cell lung cancer. Our goal is to help patients impacted by lung cancer live longer, fuller, and happier lives, as a result of our research. #research #supportresearch #lcsm #MDPhD #science

🧵🧠 A BiTE that crosses the blood-brain barrier? Tarlatamab just showed intracranial responses in SCLC brain mets — one of the hardest-to-treat populations in oncology!!! @ASCO26: DeLLphi-304: Intracranial efficacy, Presented by @g_mountzios #SCLC @SclcSMASHERS @drshieldsmd 👇Key takeaways 👇